Acute Hypoxemic Respiratory FailureNCT03513809
Inflammation and Distribution of Pulmonary Ventilation Before and After Tracheal Intubation in ARDS Patients
An observational study of Acute Hypoxemic Respiratory Failure and Acute Respiratory Distress Syndrome, run by Pontificia Universidad Catolica de Chile at 1 site in Chile.
Trial summary
Spontaneous breathing efforts in patients with respiratory failure connected to mechanical ventilation, has been associated with strong respiratory muscles activity. However, these mechanisms may will be present in patients with acute lung deseases who are breathing with no ventilatory support. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Hypoxemic Respiratory Failure, Acute Respiratory Distress Syndrome
- What is being tested?
- Thoracic electrical impedance tomography
- Type of treatment
- Medical device
- How many people
- 40 participants
- Where
- 1 siteChile
- Study dates
- 8 Jun 2017to 31 Mar 2021
- How long will I take part?
- 4 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients admitted to the ICU of the Hospital Clínico UC-Christus, Santiago de Chile, with diagnosis of acute hypoxemic respiratory failure, but who are still ventilating spontaneously.
Who may be able to join
- Acute respiratory symptoms for less than seven days
- Acute hypoxemic respiratory failure defined by a ratio of partial pressure of arterial oxygen (Pao2) to Fio2 of 300 mm Hg or less, while breathing with standard oxygen mask at FiO2 > or equal to 30%
- Increased work of breathing defined by either:
- Respiratory rate > 25 / min, or ii. Signs of intercostal or supraclavicular retraction
- Less than 24 hours since criteria 2 and 3 are met.
Who cannot join
- Acute respiratory failure secondary to exacerbation of chronic respiratory disease or to cardiogenic pulmonary edema, PaCO2 > 45 mm Hg, decreased conscious level (Glasgow Coma Scale < 13), urgent need for endotracheal intubation, a decision not to resuscitate, and consent refusal.
Trial locations and contacts
1 site in 1 country.
Chile1 site, 1 recruiting
- Recruiting
Hospital Clínico Universidad Católica
Santiago
Jaime A Retamal, 56 9 4261 1087, jaimeretamal@gmail.com
María C Bachmann, 56973838527, mcbachmann@uc.cl
About this study
Official title: Spontaneous Breathing and Progression of Lung Injury in Acute Respiratory Distress Syndrome Before Connection to Mechanical Ventilation
Spontaneous breathing efforts in patients with respiratory failure connected to mechanical ventilation, has been associated with strong respiratory muscles activity. However, these mechanisms may will be present in patients with acute lung deseases who are breathing with no ventilatory support.
We hypothesize that spontaneous breathing during acute respiratory failure could induced lung inflammation and worsen lung damage. Hereby, the connection to a ventilatory support tool, may protect the lungs from spontaneous ventilation-induced lung injury.
To test our hypothesis, our aim is to determine the effects of spontaneous breathing in acute respiratory failure patients, on lung injury distribution; and to determine whether early controlled mechanical ventilation can avoid these deleterious effects by improving air distribution.
Read the detailed description
Prospective clinical protocol in patients admitted to the ICU of the Hospital Clínico UC-Christus, Santiago de Chile, with diagnosis of acute hypoxemic respiratory failure, but who are still ventilating spontaneously.
Clinical data:
After hospital admission, patients who meet inclusion/exclusion criteria will be asked to consent to participate in the study protocol. Patients will be monitored conventionally according with hospital protocols (continuous ECG, SpO2, invasive arterial pressure, and intermittent arterial blood gases).
EIT Monitoring:
An EIT belt will be installed around the patient thorax connected to Enlight impedance tomography monitor (Dixtal, São Paulo, Brazil). EIT data will be recorded during periods of 3 minutes for offline analysis. Regional distribution of ventilation will be analyzed by dividing the image in four ROIs, each covering 25% of the ventro-dorsal distance encompassing the whole lung area. In addition we will estimate recruitment-derecruitment, and overdistention, regionally. In addition, pendelluft phenomena, and spatial patterns of regional deformation will be assessed.
Study protocol:
After patient inclusion, the first EIT and physiological data acquisition will be recorded (hemodynamics, respiratory variables, arterial blood gases, plasma samples). The data acquisition will be repeated every 6 hours from enrollment until intubation, or upto 24 hours of follow up, after which the patient will only be followed for clinically relevant outcomes. If within 24 hours of inclusion the attending physician decides intubation and connection to MV, an extra assessment of EIT, clinical data and blood samples will be performed. After intubation these assessments will include MV data and will be repeated hourly for the first 6 hours, and then at 12, 18 and 24 hours thereafter.
Bronchoalveolar lavages:
Immediately after intubation and initial stabilization, a fiberoptic bronchoscope-guided distal-protected small volume bronchoalveolar lavage (FODP mini-BAL) will be performed. This early BAL will be used as representative of the previous period of spontaneous ventilation. After 48 hours of controlled MV a new BAL will be performed, at the same regions than the first BAL, to compare the changes in the pattern of regional inflammation. For each BAL one or two aliquots of 20 ml of warmed (37°C) sterile isotonic saline will be administered and subsequently recovered in dorsal (lateral inferior) and ventral segments (medial lobe or lingula). The first recovered aliquot will be discarded while the remaining BAL fluid will be rapidly filtered through a sterile gauze and spun at 4°C at 400 x g for 15 min. The supernatant will be centrifuged at 80,000 x g for 30 min at 4°C in order to remove the surfactant-rich fraction and then divided into aliquots and frozen at - 80 °C for subsequent cytokine and mechanotransduction markers determinations.
- BAL samples will only be collected if the attending physician determines that this procedure is clinically necessary.
Cytokine analysis in serum, BALF and tissue supernatants:
Quantification of TNF-α, IL-1β, IL-6, IL-8 and IL-10 levels in plasma at time to inclusion, intubation, and 24 and 48 hours after intubation. BALF will be analyzed to determine quantification of neutrophils, cytokines (TNF-α, IL-1β, IL-6, IL-8 and IL-10) and TGF-β (extracellular cytokine with mechanotransduction proprieties) at intubation time and 48 hours after intubation.
Gas Exchange, Hemodynamics, and Ventilatory Data:
At each time of physiological acquisition we will collect arterial and central venous blood gases (if central venous catheter is present). We will assess hemodynamics (arterial blood pressure, central venous pressure, central venous pressure inspiratory swings, heart rate), and ventilatory parameters. While patients remain in spontaneous ventilation we will assess respiratory rate, ventilatory pattern, and Borg dyspnea score. After intubation and connection to MV we will collect full ventilatory data from the pneumotach system for later analysis of flows, pressures and volumes.
Statistical Analysis:
For the clinical protocol we don´t have previous data about distribution of ventilation between dependent and non-dependent lung regions during spontaneous ventilation. Therefore, we calculated sample size based on an expected effect size of 0.5, with a standard deviation two times larger, between the period of spontaneous ventilation before intubation, and the period of controlled MV after intubation. For a power of 0.8 and a two-sided error of 0.05 the calculated sample size is 32. However, of the included patients, only a fraction will be intubated, so we calculated that 60 to 80 patients must be included during the 4-year period, to complete the required number of patients available for before-after analysis. We will express values as means - standard deviation (SD) or median - range where appropriate. The Shapiro-Wilk test will be used to test data for normality. Groups will be compared using Student's t-test or Mann-Whitney U-test, one-way (repeated-measures) analysis of variance (ANOVA) or Kruskal- Wallis test. Interactions between groups and time will be assessed with two-way repeated-measures ANOVA. The Bonferroni adjustment for multiple tests will be applied for post hoc comparisons. The statistical analyses will be conducted by SPSS v.20.0.0 software (SPSS, Inc, Chicago, IL, USA), and GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA).
- Being tested
- Thoracic electrical impedance tomography
- Keywords
- Acute Hypoxemic Respiratory Failure, Acute Respiratory Distress Syndrome, Electrical impedance tomography, Spontaneous breathing, Ventilation induced-lung injury, Patient self-inflicted lung injury
- Medical subject headings
- Respiratory Insufficiency, Respiratory Distress Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Thoracic electrical impedance tomographyDevice
Non invasive, radiation-free, bedside monitoring tool for distribution of pulmonary ventilation.
| Study group | Role | What they receive |
|---|---|---|
| Acute hypoxemic respiratory failure | Patients with acute hypoxemic respiratory failure breathing spontaneously with no requirements of immediate intubation connected to thoracic electrical impedance tomography. Receives: Device: Thoracic electrical impedance tomography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Inflammation
Cytokine analysis (TNF-α, IL-1β, IL-6, IL-8 and IL-10) in serum, bronchoalveolar lavage fluid (BALF) and tissue supernatants.
Measured: Plasma: At the time of enrollment and 48 hours post intubation. BALF: Immediately post intubation and 48-96 hours post intubation (only if it is required and indicated by the attending physician).
Secondary outcomes (1)
Pulmonary ventilation distribution
Regional pulmonary ventilation distribution at bedside with electrical impedance tomography
Measured: Every 6 hours from enrollment to intubation and after connection to mechanical ventilation each hour for the first 6 hours and then at 12, 18, 24 and 48 hours.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2018
- Study start8 Jun 2017
- Primary completion21 Mar 2021 (estimated)
- Study completion31 Mar 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Acute Hypoxemic Respiratory FailureStudies of the same condition, open and under way.
- More trials run by Pontificia Universidad Catolica de ChileThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
- Target duration
- 4 Days
Sponsor and investigators
- Lead sponsor
- Pontificia Universidad Catolica de Chile
- Sponsor type
- University, hospital or other
- Collaborators
- Comisión Nacional de Investigación Científica y Tecnológica
- Responsible party
- Principal investigator, Jaime Retamal, Pontificia Universidad Catolica de Chile
- Investigators
- Jaime A Retamal, Principal investigator, Pontificia Universidad Catolica de Chile
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03513809
- Sponsor's protocol ID
- 170315007
- Other IDs
- 1171810
- Status last verified
- Mar 2021
- First submitted
- 19 Apr 2018
- Last updated
- 10 Mar 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There isn't plan for IPD
Publications
Brochard L. Ventilation-induced lung injury exists in spontaneously breathing patients with acute respiratory failure: Yes. Intensive Care Med. 2017 Feb;43(2):250-252. doi: 10.1007/s00134-016-4645-4. Epub 2017 Jan 10. No abstract available.
PubMed 28074228Mascheroni D, Kolobow T, Fumagalli R, Moretti MP, Chen V, Buckhold D. Acute respiratory failure following pharmacologically induced hyperventilation: an experimental animal study. Intensive Care Med. 1988;15(1):8-14. doi: 10.1007/BF00255628.
PubMed 3230208Yoshida T, Uchiyama A, Fujino Y. The role of spontaneous effort during mechanical ventilation: normal lung versus injured lung. J Intensive Care. 2015 Jun 17;3:18. doi: 10.1186/s40560-015-0083-6. eCollection 2015.
PubMed 27408729Yoshida T, Fujino Y, Amato MB, Kavanagh BP. Fifty Years of Research in ARDS. Spontaneous Breathing during Mechanical Ventilation. Risks, Mechanisms, and Management. Am J Respir Crit Care Med. 2017 Apr 15;195(8):985-992. doi: 10.1164/rccm.201604-0748CP.
PubMed 27786562Bachmann MC, Benites M, Oviedo V, Vadeghani NH, Soto D, Basoalto R, Cruces P, Jalil Y, Damiani LF, Bugedo G, Bruhn A, Retamal J. Association between controlled mechanical ventilation and systemic inflammation in acute hypoxemic respiratory failure: an observational cohort study. Crit Care. 2025 Nov 11;29(1):482. doi: 10.1186/s13054-025-05727-7.
PubMed 41219816
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Spontaneous Breathing and Progression of Lung Injury in Acute Respiratory Distress Syndrome Before Connection to Mechanical Ventilation
- ClinicalTrials.gov ID
- NCT03513809
- Acronym / sponsor ID
- 170315007
- Keywords
- Acute Hypoxemic Respiratory Failure, Acute Respiratory Distress Syndrome, Electrical impedance tomography, Spontaneous breathing, Ventilation induced-lung injury, Patient self-inflicted lung injury
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Pontificia Universidad Catolica de ChileUniversity, hospital or other
- Collaborators
- Comisión Nacional de Investigación Científica y Tecnológica
- Study start
- 8 Jun 2017 (actual)
- Primary completion
- 21 Mar 2021 (estimated)
- Study completion
- 31 Mar 2021 (estimated)
- First posted
- 2 May 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Spontaneous breathing efforts in patients with respiratory failure connected to mechanical ventilation, has been associated with strong respiratory muscles activity. However, these mechanisms may will be present in patients with acute lung deseases who are breathing with no ventilatory support.
We hypothesize that spontaneous breathing during acute respiratory failure could induced lung inflammation and worsen lung damage. Hereby, the connection to a ventilatory support tool, may protect the lungs from spontaneous ventilation-induced lung injury.
To test our hypothesis, our aim is to determine the effects of spontaneous breathing in acute respiratory failure patients, on lung injury distribution; and to determine whether early controlled mechanical ventilation can avoid these deleterious effects by improving air distribution.
Detailed description
Prospective clinical protocol in patients admitted to the ICU of the Hospital Clínico UC-Christus, Santiago de Chile, with diagnosis of acute hypoxemic respiratory failure, but who are still ventilating spontaneously.
Clinical data:
After hospital admission, patients who meet inclusion/exclusion criteria will be asked to consent to participate in the study protocol. Patients will be monitored conventionally according with hospital protocols (continuous ECG, SpO2, invasive arterial pressure, and intermittent arterial blood gases).
EIT Monitoring:
An EIT belt will be installed around the patient thorax connected to Enlight impedance tomography monitor (Dixtal, São Paulo, Brazil). EIT data will be recorded during periods of 3 minutes for offline analysis. Regional distribution of ventilation will be analyzed by dividing the image in four ROIs, each covering 25% of the ventro-dorsal distance encompassing the whole lung area. In addition we will estimate recruitment-derecruitment, and overdistention, regionally. In addition, pendelluft phenomena, and spatial patterns of regional deformation will be assessed.
Study protocol:
After patient inclusion, the first EIT and physiological data acquisition will be recorded (hemodynamics, respiratory variables, arterial blood gases, plasma samples). The data acquisition will be repeated every 6 hours from enrollment until intubation, or upto 24 hours of follow up, after which the patient will only be followed for clinically relevant outcomes. If within 24 hours of inclusion the attending physician decides intubation and connection to MV, an extra assessment of EIT, clinical data and blood samples will be performed. After intubation these assessments will include MV data and will be repeated hourly for the first 6 hours, and then at 12, 18 and 24 hours thereafter.
Bronchoalveolar lavages:
Immediately after intubation and initial stabilization, a fiberoptic bronchoscope-guided distal-protected small volume bronchoalveolar lavage (FODP mini-BAL) will be performed. This early BAL will be used as representative of the previous period of spontaneous ventilation. After 48 hours of controlled MV a new BAL will be performed, at the same regions than the first BAL, to compare the changes in the pattern of regional inflammation. For each BAL one or two aliquots of 20 ml of warmed (37°C) sterile isotonic saline will be administered and subsequently recovered in dorsal (lateral inferior) and ventral segments (medial lobe or lingula). The first recovered aliquot will be discarded while the remaining BAL fluid will be rapidly filtered through a sterile gauze and spun at 4°C at 400 x g for 15 min. The supernatant will be centrifuged at 80,000 x g for 30 min at 4°C in order to remove the surfactant-rich fraction and then divided into aliquots and frozen at - 80 °C for subsequent cytokine and mechanotransduction markers determinations.
- BAL samples will only be collected if the attending physician determines that this procedure is clinically necessary.
Cytokine analysis in serum, BALF and tissue supernatants:
Quantification of TNF-α, IL-1β, IL-6, IL-8 and IL-10 levels in plasma at time to inclusion, intubation, and 24 and 48 hours after intubation. BALF will be analyzed to determine quantification of neutrophils, cytokines (TNF-α, IL-1β, IL-6, IL-8 and IL-10) and TGF-β (extracellular cytokine with mechanotransduction proprieties) at intubation time and 48 hours after intubation.
Gas Exchange, Hemodynamics, and Ventilatory Data:
At each time of physiological acquisition we will collect arterial and central venous blood gases (if central venous catheter is present). We will assess hemodynamics (arterial blood pressure, central venous pressure, central venous pressure inspiratory swings, heart rate), and ventilatory parameters. While patients remain in spontaneous ventilation we will assess respiratory rate, ventilatory pattern, and Borg dyspnea score. After intubation and connection to MV we will collect full ventilatory data from the pneumotach system for later analysis of flows, pressures and volumes.
Statistical Analysis:
For the clinical protocol we don´t have previous data about distribution of ventilation between dependent and non-dependent lung regions during spontaneous ventilation. Therefore, we calculated sample size based on an expected effect size of 0.5, with a standard deviation two times larger, between the period of spontaneous ventilation before intubation, and the period of controlled MV after intubation. For a power of 0.8 and a two-sided error of 0.05 the calculated sample size is 32. However, of the included patients, only a fraction will be intubated, so we calculated that 60 to 80 patients must be included during the 4-year period, to complete the required number of patients available for before-after analysis. We will express values as means - standard deviation (SD) or median - range where appropriate. The Shapiro-Wilk test will be used to test data for normality. Groups will be compared using Student's t-test or Mann-Whitney U-test, one-way (repeated-measures) analysis of variance (ANOVA) or Kruskal- Wallis test. Interactions between groups and time will be assessed with two-way repeated-measures ANOVA. The Bonferroni adjustment for multiple tests will be applied for post hoc comparisons. The statistical analyses will be conducted by SPSS v.20.0.0 software (SPSS, Inc, Chicago, IL, USA), and GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 4 Days
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Acute hypoxemic respiratory failure | – | Device: Thoracic electrical impedance tomographyPatients with acute hypoxemic respiratory failure breathing spontaneously with no requirements of immediate intubation connected to thoracic electrical impedance tomography. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients admitted to the ICU of the Hospital Clínico UC-Christus, Santiago de Chile, with diagnosis of acute hypoxemic respiratory failure, but who are still ventilating spontaneously.
Key inclusion criteria (5 listed)
- Acute respiratory symptoms for less than seven days
- Acute hypoxemic respiratory failure defined by a ratio of partial pressure of arterial oxygen (Pao2) to Fio2 of 300 mm Hg or less, while breathing with standard oxygen mask at FiO2 > or equal to 30%
- Increased work of breathing defined by either:
- Less than 24 hours since criteria 2 and 3 are met.
Key exclusion criteria (1 listed)
- Acute respiratory failure secondary to exacerbation of chronic respiratory disease or to cardiogenic pulmonary edema, PaCO2 > 45 mm Hg, decreased conscious level (Glasgow Coma Scale < 13), urgent need for endotracheal intubation, a decision not to resuscitate, and consent refusal.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Thoracic electrical impedance tomographyNon invasive, radiation-free, bedside monitoring tool for distribution of pulmonary ventilation. | Device | Acute hypoxemic respiratory failure |
Primary outcome
Inflammation
Time frame: Plasma: At the time of enrollment and 48 hours post intubation. BALF: Immediately post intubation and 48-96 hours post intubation (only if it is required and indicated by the attending physician).
Cytokine analysis (TNF-α, IL-1β, IL-6, IL-8 and IL-10) in serum, bronchoalveolar lavage fluid (BALF) and tissue supernatants.
1 secondary outcome
Pulmonary ventilation distribution
Time frame: Every 6 hours from enrollment to intubation and after connection to mechanical ventilation each hour for the first 6 hours and then at 12, 18, 24 and 48 hours.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2021.
- Results publication: PubMed 28074228Brochard L. Ventilation-induced lung injury exists in spontaneously breathing patients with acute respiratory failure: Yes. Intensive Care Med. 2017 Feb;43(2):250-252. doi: 10.1007/s00134-016-4645-4. Epub 2017 Jan 10. No abstract available.
- Results publication: PubMed 3230208Mascheroni D, Kolobow T, Fumagalli R, Moretti MP, Chen V, Buckhold D. Acute respiratory failure following pharmacologically induced hyperventilation: an experimental animal study. Intensive Care Med. 1988;15(1):8-14. doi: 10.1007/BF00255628.
- Results publication: PubMed 27408729Yoshida T, Uchiyama A, Fujino Y. The role of spontaneous effort during mechanical ventilation: normal lung versus injured lung. J Intensive Care. 2015 Jun 17;3:18. doi: 10.1186/s40560-015-0083-6. eCollection 2015.
- Results publication: PubMed 27786562Yoshida T, Fujino Y, Amato MB, Kavanagh BP. Fifty Years of Research in ARDS. Spontaneous Breathing during Mechanical Ventilation. Risks, Mechanisms, and Management. Am J Respir Crit Care Med. 2017 Apr 15;195(8):985-992. doi: 10.1164/rccm.201604-0748CP.
- Derived from this study: PubMed 41219816Bachmann MC, Benites M, Oviedo V, Vadeghani NH, Soto D, Basoalto R, Cruces P, Jalil Y, Damiani LF, Bugedo G, Bruhn A, Retamal J. Association between controlled mechanical ventilation and systemic inflammation in acute hypoxemic respiratory failure: an observational cohort study. Crit Care. 2025 Nov 11;29(1):482. doi: 10.1186/s13054-025-05727-7.
- Individual participant dataSharing planned: No. There isn't plan for IPD
Related trials for Acute Hypoxemic Respiratory Failure
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Recruiting
Bedside Spirometry for Acute Lung Injury
Respiratory Insufficiency
Recruiting
Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure
Acute Respiratory Distress Syndrome (ARDS), Acute Hypoxemic Respiratory Failure
RecruitingObservational study
Brain-lung Interaction During Acute Respiratory Failure
Acute Respiratory Failure
RecruitingPhase 2
Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study
Acute Hypoxemic Respiratory Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jaime A Retamal principal investigator
Pontificia Universidad Catolica de Chile
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Hypoxemic Respiratory Failure and Acute Respiratory Distress Syndrome, run by Pontificia Universidad Catolica de Chile at 1 site in Chile.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jaime A Retamal (56942611087, jaimeretamal@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Inflammation (time frame: Plasma: At the time of enrollment and 48 hours post intubation. BALF: Immediately post intubation and 48-96 hours post intubation (only if it is required and indicated by the attending physician).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03513809, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2021.